These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 17989689)

  • 1. Complement-targeted therapeutics.
    Ricklin D; Lambris JD
    Nat Biotechnol; 2007 Nov; 25(11):1265-75. PubMed ID: 17989689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L
    Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic complement inhibition – from experimental to clinical medicine.
    Lappegård KT; Bjerre A; Tjønnfjord GE; Mollnes TE
    Tidsskr Nor Laegeforen; 2015 Oct; 135(19):1745-9. PubMed ID: 26486669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the complement cascade: novel treatments coming down the pike.
    Thurman JM; Le Quintrec M
    Kidney Int; 2016 Oct; 90(4):746-52. PubMed ID: 27325183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement in human disease: approved and up-and-coming therapeutics.
    West EE; Woodruff T; Fremeaux-Bacchi V; Kemper C
    Lancet; 2024 Jan; 403(10424):392-405. PubMed ID: 37979593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue-targeted complement therapeutics.
    Tomlinson S; Thurman JM
    Mol Immunol; 2018 Oct; 102():120-128. PubMed ID: 30220307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement-targeted therapeutics: An emerging field enabled by academic drug discovery.
    Lamers C; Ricklin D; Lambris JD
    Am J Hematol; 2023 May; 98 Suppl 4():S82-S89. PubMed ID: 36755352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of complement inhibition in kidney transplantation.
    Legendre C; Sberro-Soussan R; Zuber J; Frémeaux-Bacchi V
    Br Med Bull; 2017 Dec; 124(1):5-17. PubMed ID: 29069327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CR2-mediated targeting of complement inhibitors: bench-to-bedside using a novel strategy for site-specific complement modulation.
    Holers VM; Rohrer B; Tomlinson S
    Adv Exp Med Biol; 2013; 735():137-54. PubMed ID: 23402024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease.
    de Boer ECW; van Mourik AG; Jongerius I
    Front Immunol; 2020; 11():578069. PubMed ID: 33362763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical promise of next-generation complement therapeutics.
    Mastellos DC; Ricklin D; Lambris JD
    Nat Rev Drug Discov; 2019 Sep; 18(9):707-729. PubMed ID: 31324874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement: A primer for the coming therapeutic revolution.
    Barnum SR
    Pharmacol Ther; 2017 Apr; 172():63-72. PubMed ID: 27914981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics.
    Patriquin CJ; Kuo KHM
    Transfus Med Rev; 2019 Oct; 33(4):256-265. PubMed ID: 31703946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From orphan drugs to adopted therapies: Advancing C3-targeted intervention to the clinical stage.
    Mastellos DC; Reis ES; Yancopoulou D; Hajishengallis G; Ricklin D; Lambris JD
    Immunobiology; 2016 Oct; 221(10):1046-57. PubMed ID: 27353192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eculizumab in the treatment of neuromyelitis optica spectrum disorder.
    Giglhuber K; Berthele A
    Immunotherapy; 2020 Oct; 12(14):1053-1066. PubMed ID: 32772617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New Complement Therapeutics in Complement-Related Diseases].
    Wakamiya N; Ohtani K; Hidaka Y; Inoue N
    Brain Nerve; 2019 Jun; 71(6):555-564. PubMed ID: 31171752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A computational model for the evaluation of complement system regulation under homeostasis, disease, and drug intervention.
    Zewde N; Morikis D
    PLoS One; 2018; 13(6):e0198644. PubMed ID: 29874282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.
    Mastellos DC; Reis ES; Yancopoulou D; Risitano AM; Lambris JD
    Semin Hematol; 2018 Jul; 55(3):167-175. PubMed ID: 30032754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New milestones ahead in complement-targeted therapy.
    Ricklin D; Lambris JD
    Semin Immunol; 2016 Jun; 28(3):208-22. PubMed ID: 27321574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Complement Therapeutics in Development as Potential Treatment for Renal Disease.
    Kelleher C; Kocinsky H
    Adv Chronic Kidney Dis; 2020 Mar; 27(2):95-103. PubMed ID: 32553251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.